Putting the BRK on breast cancer: From molecular target to therapeutics

Putting the BRK on breast cancer: From molecular target to therapeutics

10.7150/thno.49716

Saved in:

Bibliographic Details
Main Authors:	Ang, Hui Li, Yuan, Yi, Lai, Xianning, Tan, Tuan Zea, Wang, Lingzhi, Huang, Benjamin BoJun, Pandey, Vijay, Huang, Ruby Yun-Ju, Lobie, Peter E, Goh, Boon Cher, Sethi, Gautam, Yap, Celestial T, Chan, Ching Wan, Lee, Soo Chin, Kumar, Alan Prem
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Review
Language:	English
Published:	IVYSPRING INT PUBL 2023
Subjects:	Science & Technology Life Sciences & Biomedicine Medicine, Research & Experimental Research & Experimental Medicine Breast tumor kinase (BRK) hallmarks of cancer chemical inhibitors molecular inhibitors meta-analysis PROTEIN-TYROSINE KINASE MAMMARY EPITHELIAL-CELLS LONG-TERM SURVIVAL SH2-KINASE LINKER SIGNALING PATHWAY OLEANOLIC ACID SH3 DOMAIN FACTOR-I PTK6 GROWTH
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/237218
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Crystallization trials of Refolded Breast Tumor Kinase (BRK) and Peroxisome Proteins
by: NGUYEN QUOC TOAN
Published: (2010)

Molecular docking, conformational analysis, and 3D QSAR model building for TBK-1 inhibition
by: Rallos, Kiana Casenas, et al.
Published: (2022)

ENGINEERING NOVEL COMPOUNDS AS SPHINGOSINE KINASE INHIBITORS
by: WONG LINGKAI
Published: (2011)

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
by: Salto-Tellez, M., et al.
Published: (2014)

Influences of phosphorylation on Thr14/Tyr15 in CDK5 in the presence of roscovitine/ATP and HHASPRK
by: Jin, H.-X., et al.
Published: (2014)

CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance
by: Wu, Ling, et al.
Published: (2023)

Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing
by: Ho, H.K., et al.
Published: (2014)

MECHANISMS OF HYPOXIA-INDUCED GROWTH AND TYROSINE KINASE INHIBITOR RESISTANCE IN CHRONIC MYELOID LEUKEMIA
by: MANJERI ADITI SUBRAMANIAM
Published: (2019)

Functional Effects of a Novel BIM Deletion Polymorphism in Mediating Resistance to Tyrosine Kinase Inhibitors in Cancer
by: JUAN WEN CHUN
Published: (2014)

Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer
by: Collins, Denis M., et al.
Published: (2020)

Potential roles for the PIM1 kinase in human cancer - A molecular and therapeutic appraisal
by: Shah, N., et al.
Published: (2012)

Tannic acid, a potent inhibitor of epidermal growth factor receptor tyrosine kinase
by: Yang, E.B., et al.
Published: (2014)

Increased iNOS in transformed HPV-immortalized human keratinocytes following chronic ethanol treatment
by: Warangkana Chunglok
Published: (2023)

Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)
by: Lin, L., et al.
Published: (2016)

IDENTIFICATION OF A THERAPEUTIC COMPOUND TARGETING THE CORE ONCOGENIC MACHINERY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
by: LIM FANG QI
Published: (2022)

Identification and characterization of a predominant isoform of human MKK3
by: Han, J., et al.
Published: (2014)

Activation of protein kinases and the inactivation of protein phosphatase 2A in tumour necrosis factor and interleukin-1 signal-transduction pathways
by: Guy, G.R., et al.
Published: (2011)

Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis
by: Budman, D.R., et al.
Published: (2014)

Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
by: Teo, Y.L., et al.
Published: (2014)

Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment
by: Jin, F., et al.
Published: (2014)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
by: Barrios, C.H., et al.
Published: (2014)

Molecular dynamics simulations on the inhibition of Cyclin-dependent kinases 2 and 5 in the presence of activators
by: Zhang, B., et al.
Published: (2014)

Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer
by: Collins, D.M., et al.
Published: (2021)

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
by: Chin, T.-M., et al.
Published: (2021)

Design and synthesis of receptor tyrosine kinase inhibitors for anticancer treatment
by: Chawannuch Mudjupa
Published: (2023)

EXPLORING THE ROLE OF PHARMACOKINETIC ALTERATIONS IN TYROSINE KINASE INHIBITORS (TKIS)-ASSOCIATED TOXICITIES
by: TEO YI LING
Published: (2015)

SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF RESORCYLIC ACID LACTONES AND DERIVATIVES AS PROTEIN KINASE INHIBITORS TARGETING TO CANCERS
by: XU JIN
Published: (2015)

NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy
by: Shen, H.-M., et al.
Published: (2014)

Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor
by: Jin, F., et al.
Published: (2014)

Exploring aigialomycin D and its analogues as protein kinase inhibitors for cancer targets
by: Xu, J., et al.
Published: (2014)

Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer
by: Chan, D., et al.
Published: (2014)

CLINICAL AND FUNCTIONAL SIGNIFICANCE OF CD151 IN WILDTYPE EGRF NSCLC
by: WONG HUEE PING AMANDA
Published: (2020)

Development of phosphodiesterase–protein-kinase complexes as novel targets for discovery of inhibitors with enhanced specificity
by: Tulsian, Nikhil K., et al.
Published: (2022)

Crystal structure of human vaccinia-related kinase 1 in complex with AMP-PNP, a non-hydrolyzable ATP analog
by: Ngow, Yeen Shian, et al.
Published: (2019)

Immunoglobulin-associated creatine kinase masquerading as macro-creatine kinase type 2 in a statin user
by: Loh, T.P., et al.
Published: (2014)

How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?
by: Chan, A., et al.
Published: (2014)

Macro creatine kinase
by: Viroj Wiwanikit
Published: (2006)

The Ccl1–Kin28 kinase complex regulates autophagy under nitrogen starvation
by: Zhu, Jing, et al.
Published: (2017)

Effect of Genistein on ATP-induced Cell Retraction and Rounding in Human Chang Liver Cells
by: Bay, B.H.
Published: (2012)

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma
by: Lee, S.-C., et al.
Published: (2012)